InflaRx (NASDAQ:IFRX) Shares Purchased by Raymond James Financial Services Advisors Inc.

Raymond James Financial Services Advisors Inc. boosted its holdings in InflaRx (NASDAQ:IFRX) by 18.2% during the fourth quarter, Holdings Channel reports. The institutional investor owned 317,859 shares of the company’s stock after buying an additional 48,944 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in InflaRx were worth $518,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its stake in InflaRx by 7,966.1% in the 4th quarter. JPMorgan Chase & Co. now owns 9,760 shares of the company’s stock worth $30,000 after buying an additional 9,639 shares during the last quarter. BNP Paribas Arbitrage SNC purchased a new position in shares of InflaRx in the 2nd quarter worth about $95,000. Virtu Financial LLC purchased a new position in shares of InflaRx in the 1st quarter worth about $53,000. Geode Capital Management LLC raised its holdings in shares of InflaRx by 18.9% in the 2nd quarter. Geode Capital Management LLC now owns 31,294 shares of the company’s stock worth $140,000 after purchasing an additional 4,967 shares during the period. Finally, Alps Advisors Inc. raised its holdings in shares of InflaRx by 109.4% in the 3rd quarter. Alps Advisors Inc. now owns 83,279 shares of the company’s stock worth $248,000 after purchasing an additional 43,501 shares during the period. 42.39% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of InflaRx in a report on Friday, March 22nd.

InflaRx Price Performance

InflaRx stock opened at $1.35 on Friday. The company has a market cap of $79.49 million, a price-to-earnings ratio of -1.57 and a beta of 1.27. InflaRx has a 12 month low of $1.14 and a 12 month high of $5.20. The stock’s 50-day moving average is $1.56 and its 200-day moving average is $1.64.

InflaRx (NASDAQ:IFRX) last announced its earnings results on Thursday, March 21st. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.10). Research analysts anticipate that InflaRx will post -1 EPS for the current year.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.